Summary of Novo Nordisk Earnings Report

Date: November 4, 2026

Key Highlights

• Revenue: 79.2 billion DKK, exceeding market expectations of 73.5 billion DKK.
• Adjusted operating profit: Increased by 34% to 31.72 billion DKK, driven by strong sales of oral Wegovy.
• Management upgraded full-year guidance for adjusted revenue and operating profit to a range of -2% to +2%.

Market Reaction

Initially, Novo Nordisk's shares rose by as much as 5% following the earnings announcement, but the gains were moderated to around 2% as the market adjusted. This behavior may indicate a cautious optimism regarding the company's operational conditions, which have been under pressure for several months.

Financial Performance

The company's revenue showed a year-on-year increase of 6%, significantly above market consensus. The standout performer was the oral Wegovy, which saw sales rise by 53% quarter-on-quarter, contributing to a total of 5.39 billion DKK in revenue. The obesity treatment segment overall generated 26.15 billion DKK, marking a 24% increase year-on-year.

Net Profit Concerns

Despite the revenue and operating profit growth, net profit fell by 16% year-on-year to 16.7 billion DKK. This decline raises concerns about the sustainability of the earnings improvement, as it suggests that the company is still experiencing profit erosion.

Impairments and Adjustments

Reported EBIT was impacted by 8.7 billion DKK in impairments, which included 4.6 billion DKK related to ziltivekimab and 4.1 billion DKK for adjustments to the production network. While these impairments are non-cash, they indicate a loss in value of previous investments, complicating the narrative of operational improvement.

Future Outlook

Management's guidance appears more optimistic than the results themselves, with an upgraded outlook for both adjusted revenue and operating profit. However, the key challenge remains whether the expansion of oral drugs can counteract pricing pressures and competition. Starting January 2027, Novo plans to reduce US list prices for Wegovy and Ozempic by approximately 50% and 35%, respectively.

Investors are also looking forward to the potential launch of CagriSema in the US in early 2027, pending regulatory approval, which could serve as a positive catalyst for the company's growth.

Conclusion

Overall, while Novo Nordisk's latest earnings report shows some positive trends, the decline in net profit and the presence of significant impairments highlight ongoing challenges. The company's ability to navigate pricing pressures and competition will be crucial for its future performance.